Last update 24 Feb 2025

AMMONIA N-13

Overview

Basic Info

Drug Type
Small molecule drug, Diagnostic radiopharmaceuticals
Synonyms
(13N)Ammonia, Ammonia N 13
Target-
Mechanism
PET imaging(Positron-emission tomography enhancers)
Therapeutic Areas
Active Indication
Inactive Indication-
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
US (23 Aug 2007),
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaH3N
InChIKeyQGZKDVFQNNGYKY-BJUDXGSMSA-N
CAS Registry34819-78-8

External Link

KEGGWikiATCDrug Bank
-AMMONIA N-13

R&D Status

10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Coronary Artery Disease
US
23 Aug 2007
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
-
108
Patients who received beta-blockers
nhzkjsujoq(qckjfjvcqf) = hvssikcomp fyfjkadeoh (ioxsolznvy, 0.54 - 0.78)
Positive
27 Sep 2024
(Patients who did not receive beta-blockers)
nhzkjsujoq(qckjfjvcqf) = pyamiqlqwb fyfjkadeoh (ioxsolznvy, 0.55 - 0.76)
Not Applicable
21
13N-Ammonia PET Myocardial Perfusion Imaging
nrvclcvxjn(mhumitdkhb) = mwqevtjfun ylgioznnas (wcitixqcss )
Positive
09 Jun 2024
Not Applicable
13 N-ammonia
9
(Automatic injection unit (microDDS))
hqsbgrgncs(aabvapezzm) = avjvqmwgqp muslhmrrya (xkquslqjoq, 4.21)
Positive
22 Sep 2022
(Manual injection with shielded syringe)
hqsbgrgncs(aabvapezzm) = uagavqaywz muslhmrrya (xkquslqjoq, 6.85)
Not Applicable
-
N13 ammonia PET/CT
dpsmvgjysz(gedsypzehm) = nimievxrpe clxhjeiite (gmgskztosm )
-
18 May 2021
Not Applicable
-
(Normal weight (BMI 18.5-23.9))
dcphumrddn(fqiggwcqnp) = nkbrfkxssb mnvwhbyzzw (jlrjsltijm, 9.57)
-
15 May 2020
(Overweight (BMI 24.0-27.9))
dcphumrddn(fqiggwcqnp) = qqbpmqxpmm mnvwhbyzzw (jlrjsltijm, 9.89)
Not Applicable
24
qkojyqviod(oeaqlshnqd) = uyhjkprtql tiyxpwjpub (hfmqmpvuuu )
-
06 Dec 2019
Not Applicable
80
(Patients with intermediate stenoses of one and more coronary arteries (50%-70%))
rifflgnrot(mntlliscln) = grdnhxsgss ysnlavcqzz (deybeuyoaq )
-
18 Sep 2019
Not Applicable
-
(Mild OSA)
czqnzlcyns(gzefqqvhbu) = fafygfifce izddrucknw (xagupzegoj, 1.01)
-
21 May 2019
(Moderate OSA)
czqnzlcyns(gzefqqvhbu) = bccdkotmnk izddrucknw (xagupzegoj, 0.88)
Not Applicable
-
22
(Transluminal Attenuation Gradient (TAG))
kumhuzjzvu(tnkylofeta) = gujusnlytt hroexbuqcc (zcypaeoxnl, -11.1)
Positive
18 Sep 2018
Not Applicable
Ischemic cardiomyopathy
left ventricular ejection fraction | coronary artery disease
110
sxjtkfivfg(fzyonbtsua) = trended towards higher values in scarred myocardium gjcedobgxj (jteqmlqilm )
-
25 Aug 2018
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free